[Pituitary metastases: a diagnostic and therapeutic challenge]
Mónica G Loto,Amelia Rogozinski,Analia Alfieri,María C Ballarino,María F Battistone,Alberto Chervin,Karina D Danilowicz,Sabrina Diez,Patricia Fainstein Day,Alejandra Furioso,Mariela Glerean,Mariana Gonzalez Pernas,Débora Katz,María S Mallea Gil,Marcela Martinez,Karina A Miragaya,Maria I Sabate,Patricia Slavinsky,Soledad Sosa,Gabriela Szuman,Julieta Tkatch,Marcelo N Vitale,Mirtha Guitelman
Abstract:Introduction: Sellar metastases (SM) are rare manifestations of malignancy. Breast and lung cancer are the most common primary tumors. Most cases are diagnosed in patients with advanced malignant disease; however, symptoms of pituitary involvement can precede the diagnosis of the primary tumor. Methods: Retrospective analysis of symptoms at presentation, hormonal, radiological and histological findings, management, and outcome of patients with SM from 2009 to 2020. Results: Eighteen patients'cases were included, 11 with histological confirmation. Median (m) age was 53 years (range 35-75), 53% male. Primary malignant tumors: 8 lungs, 6 breast, 1 follicular thyroid carcinoma, 1 Hodgkin lymphoma, and 2 clear cell renal carcinomas. The m time between the diagnosis of the primary neoplasm and the occurrence of the SM was 108 months (range: 11-180). In 8 patients the diagnosis of the primary neoplasm was made after the finding of the symptomatic sellar mass. Insipidus diabetes, adenohypophysis deficit, visual disorders, headache, and cranial nerve deficits were evident in 78, 77, 61, 39 and 39% of the cases, respectively. Fifteen patients harbored supra / parasellar masses, in three a lesion was limited to the pituitary gland, and stalk. Eleven out of 18 (61.1%) of the patients were operated on by the trans-sphenoidal approach, for diagnostic and / or decompressive purposes. Eighteen died, with a median survival time of 6 months (1-36). Discussion: In the presence of a pituitary lesion with diffuse gadolinium uptake, associated with insipidus diabetes and / or visual disorder SM should be suspected even in patients without a history of oncological disease.